Markets

Tuesday 9/10 Insider Buying Report: AERI, NKTR

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys.

On Monday, Aerie Pharmaceuticals' Chief Executive Officer, Vicente Anido Jr., made a $498,952 buy of AERI, purchasing 26,250 shares at a cost of $19.01 a piece. So far Anido Jr. is in the green, up about 16.2% on their buy based on today's trading high of $22.09. Aerie Pharmaceuticals is trading up about 5.1% on the day Tuesday. This purchase marks the first one filed by Anido Jr. in the past year.

And at Nektar Therapeutics, there was insider buying on Thursday, by SVP & Chief Scientific Officer Stephen K. Doberstein who bought 15,000 shares at a cost of $17.28 each, for a total investment of $259,200. Nektar Therapeutics is trading up about 10.3% on the day Tuesday. Doberstein was up about 16.9% on the purchase at the high point of today's trading session, with NKTR trading as high as $20.20 in trading on Tuesday.

VIDEO: Tuesday 9/10 Insider Buying Report: AERI, NKTR

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AERI NKTR

Other Topics

Stocks

Latest Markets Videos